Loading…
SpyGlass Pharma, Inc. is projected to rise to $23.25 by 2027, a +3% move from its current price of $22.52. SGP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $21.52 | $22.50 | $23.52 | -0.09% |
| Jul 14 | $21.11 | $22.48 | $23.93 | -0.19% |
| Jul 15 | $20.80 | $22.46 | $24.25 | -0.28% |
| Jul 16 | $20.53 | $22.44 | $24.52 | -0.37% |
| Jul 17 | $20.30 | $22.42 | $24.75 | -0.46% |
| Jul 18 | $20.09 | $22.39 | $24.96 | -0.56% |
| Jul 19 | $19.90 | $22.37 | $25.16 | -0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.90 | $22.37 | $25.16 | -0.65% |
| Week 2 | $18.83 | $22.23 | $26.24 | -1.29% |
| Week 3 | $18.03 | $22.09 | $27.06 | -1.93% |
| Week 4 | $17.36 | $21.94 | $27.74 | -2.57% |
| Week 5 | $16.77 | $21.80 | $28.33 | -3.20% |
| Week 6 | $16.25 | $21.66 | $28.86 | -3.82% |
| Week 7 | $15.78 | $21.52 | $29.34 | -4.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SpyGlass Pharma, Inc. is a biopharmaceutical company focused on treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP).
It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
These core activities position SpyGlass Pharma as a specialized provider of targeted ocular therapies and delivery systems for chronic eye conditions.
SpyGlass Pharma, Inc. trades under the ticker SGP and currently quotes at $22.52. The company has a market capitalization of $752.92M and is ranked 2757 by market cap.
The forecast landscape shows a long-term bullish price path, with a neutral stance in the near term. The 2030 average is $29.64, with an ROI of 31.6 and a bullish sentiment; the 2040 average is $51.81 with an ROI of 130.1 and bullish sentiment; the 2050 average is $101.93 with an ROI of 352.6 and bullish sentiment.
In the near term, the forecast projects neutral sentiment for 2026–2029, with 2026 average $22.52, 2027 average $23.25, 2028 average $21.80, and 2029 average $20.36.
A major floor 29.4% below — a decisive break under it would weaken the trend.
The nearest floor, 22.0% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 20.8% above — clearing it would confirm fresh momentum.
Key SGP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SGP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.33 | Buy | $20.82 | Buy |
| MA 10 | $20.54 | Buy | $20.37 | Buy |
| MA 20 | $19.63 | Buy | $20.08 | Buy |
| MA 50 | $20.80 | Buy | $20.83 | Buy |
| MA 100 | $23.17 | Sell | $22.33 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.22 | Neutral |
| Stoch RSI (14) | 92.16 | Sell |
| CCI (20) | 185.47 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.31 | Buy |
| ROC (12) | 14.49 | Buy |
| Bollinger %B (20,2) | 1.04 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.12 | Sell |
| Awesome (5,34) | 0.81 | Buy |
| Ultimate (7,14,28) | 56.50 | Neutral |
| Momentum (10) | 3.71 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 20.75 | Buy |
| ADX (14) | 15.78 | Neutral |
| ATR (14) | 0.82 | Info |
The 30-day technical picture is bullish overall. RSI(14) is at 60 and the 50-day simple moving average is $20.80, indicating positive momentum.
The stock currently sits near resistance at $22.52 with support at $17.56. The 30-day price range stretches from a low of $16.82 to a high of $30.16, highlighting notable volatility within a month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.56 | $22.52 | $28.84 | 0% | Neutral | |
| $16.05 | $23.25 | $36.53 | +3% | Neutral | |
| $13.89 | $21.80 | $36.90 | -3% | Neutral | |
| $12.09 | $20.36 | $36.47 | -10% | Neutral | |
| $16.50 | $29.64 | $55.61 | +32% | Bullish | |
| $17.78 | $33.97 | $66.32 | +51% | Bullish | |
| $16.80 | $34.07 | $68.88 | +51% | Bullish | |
| $16.99 | $36.54 | $76.21 | +62% | Bullish | |
| $14.93 | $33.17 | $71.18 | +47% | Bullish | |
| $15.77 | $35.04 | $77.16 | +56% | Bullish | |
| $23.32 | $51.81 | $119.17 | +130% | Bullish | |
| $45.87 | $101.93 | $234.45 | +353% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $17.56 | $22.52 | $27.00 | +0.00% |
| August 2026 | $16.69 | $20.48 | $26.34 | -9.06% |
| September 2026 | $16.56 | $20.69 | $27.30 | +1.04% |
| October 2026 | $16.70 | $21.19 | $28.54 | +2.39% |
| November 2026 | $16.02 | $20.60 | $28.24 | -2.76% |
| December 2026 | $15.90 | $20.71 | $28.84 | +0.51% |
Click any year to see its month-by-month SGP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SGP price prediction for 2026 points to an average of $22.52 (low $17.56, high $28.84) — a potential gain of 0% on today's $22.52. A consolidation phase looks the most probable path here.
In 2027, SGP is projected to trade between $16.05 and $36.53, averaging $23.25 — a potential gain of +3% from today's $22.52. That is up +3% on the projected 2026 average. Price action looks broadly range-bound.
SpyGlass Pharma, Inc.'s 2028 outlook centres on $21.80, within a $13.89 to $36.90 range. That is -6% versus the projected 2027 average. That marks a -3% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, SGP could reach as high as $36.47, with a base case around $20.36 and support toward $12.09 — roughly -10% from $22.52. Price action looks broadly range-bound.
Expect SGP to range from $16.50 to $55.61 through 2030. The $29.64 average target implies a +32% move from current prices. That is up +46% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The SGP price prediction for 2031 points to an average of $33.97 (low $17.78, high $66.32) — a potential gain of +51% on today's $22.52. Momentum favours further upside here.
In 2032, SGP is projected to trade between $16.80 and $68.88, averaging $34.07 — a potential gain of +51% from today's $22.52. That is up 0% on the projected 2031 average. Buyers look set to stay in control over this stretch.
SpyGlass Pharma, Inc.'s 2033 outlook centres on $36.54, within a $16.99 to $76.21 range. That is up +7% on the projected 2032 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2034, SGP could reach as high as $71.18, with a base case around $33.17 and support toward $14.93 — roughly +47% from $22.52. Buyers look set to stay in control over this stretch.
Expect SGP to range from $15.77 to $77.16 through 2035. The $35.04 average target implies a +56% move from current prices. That is up +6% on the projected 2034 average. Momentum favours further upside here.
The SGP price prediction for 2040 points to an average of $51.81 (low $23.32, high $119.17) — a potential gain of +130% on today's $22.52. Buyers look set to stay in control over this stretch.
In 2050, SGP is projected to trade between $45.87 and $234.45, averaging $101.93 — a potential gain of +353% from today's $22.52. That is up +97% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SGP today (≈ 44.404973 SGP) could be worth
$4,526.42
+$3,526.42 (+353%) by 2050 · US Dollar
Based on the average projected SGP price of $101.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SGPwould be worth at today's price.
$1,000 invested in SGP on Feb 6, 2026 (≈ 37.878788 SGP) would be worth
$853.03
-$146.97 (-14.7%) today · 0.85× · US Dollar
Based on a SGP entry price of $26.4 vs. today's $22.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.15 | $1,175.98 | +17.6% |
| 1 month ago | $17.97 | $1,253.2 | +25.3% |
| 3 months ago | $20.75 | $1,085.3 | +8.5% |
| All time ago | $26.4 | $853.03 | -14.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SGP forecast.
Our base-case forecast reaches $45.00 around 2040.
Implied market cap at $45.00: $1.5B
The multi-year forecast shows a clear bullish inflection starting in 2030. The 2030 average is $29.64 with an ROI of 31.6 and a bullish sentiment, marking a meaningful rise from near-term levels. The trajectory continues, with the 2040 average at $51.81 and an ROI of 130.1, maintaining a bullish stance.
By 2050, the average price is projected to be $101.93 with an ROI of 352.6 and a bullish sentiment, reflecting a substantial long-term appreciation potential.
The near-term outlook (2026–2029) is neutral, with 2026 min $17.56, avg $22.52, max $28.84; 2027 min $16.05, avg $23.25, max $36.53; 2028 min $13.89, avg $21.80, max $36.90; 2029 min $12.09, avg $20.36, max $36.47. These are estimates and not guarantees, and the long-run upside comes with inherent market and model uncertainty.
Tap a question to reveal the answer.
2030: The average price forecast is $29.64, with a min of $16.50 and max of $55.61, ROI 31.6, sentiment BULLISH.
Forecasts show a bullish path in the long term, with 2030 avg $29.64, 2040 avg $51.81, and 2050 avg $101.93, with ROIs of 31.6, 130.1, and 352.6, respectively, though these are estimates and not guarantees.
Yes. The 2050 forecast shows an average of $101.93 and a max of $234.45, with ROI 352.6 and a bullish sentiment, indicating potential to reach or exceed $100.
Current price is $22.52 and market cap is $752.92M.
The 30-day range is from a low of $16.82 to a high of $30.16; support is $17.56 and resistance is $22.52.
SpyGlass Pharma, Inc. Community Discussion
0Share your SpyGlass Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.